IBUMAX

This brand name is authorized in Estonia, Finland, Lithuania, Poland

Active ingredients

The drug IBUMAX contains one active pharmaceutical ingredient (API):

1 Ibuprofen
UNII WK2XYI10QM - IBUPROFEN

Ibuprofen is a propionic acid derivative NSAID that has demonstrated its efficacy by inhibition of prostaglandin synthesis. In humans ibuprofen reduces inflammatory pain, swellings and fever. Furthermore, ibuprofen reversibly inhibits platelet aggregation.

Read about Ibuprofen

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
M01AE01 Ibuprofen M Musculo-skeletal system → M01 Antiinflammatory and antirheumatic products → M01A Antiinflammatory and antirheumatic products, non-steroids → M01AE Propionic acid derivatives
Discover more medicines within M01AE01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: EE Ravimiamet Identifier(s): 1012521, 1025244, 1072987, 1073012, 1085194, 1085206, 1153178, 1153189, 1153190, 1153202, 1153213, 1362798, 1870231
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 005244, 005255, 020121, 063233, 063242, 132864, 175968, 175992, 176073, 418361
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1005065, 1005067, 1005068, 1005069, 1005070, 1023384, 1034198, 1052108, 1052111, 1088305, 1090743
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100193332, 100193639, 100193668

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.